Novartis tests new injection to ease arthritic knee pain

NCT ID NCT05462990

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested an investigational drug called QUC398 to see if it could reduce pain and slow cartilage loss in people with painful knee osteoarthritis. About 101 participants received either the drug or a placebo injection every four weeks for 12 weeks. The main goal was to measure changes in knee pain and cartilage volume to see if the treatment was effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Boston Univ School of Medicine

Boston, Massachusetts, 02118, United States
Clinical Research of West Florida Inc

Tampa, Florida, 33603, United States
Novartis Investigative Site

Southport, Queensland, 4222, Australia
Novartis Investigative Site

Christchurch, 8011, Australia
Novartis Investigative Site

St Leonards, 2065, Australia
Novartis Investigative Site

Herlev, 2730, Denmark
Novartis Investigative Site

Vejle, 7100, Denmark
Novartis Investigative Site

Nice, 06001, France
Novartis Investigative Site

Orléans, 45100, France
Novartis Investigative Site

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site

Leganés, Madrid, 28915, Spain
Novartis Investigative Site

A Coruña, 15006, Spain
Novartis Investigative Site

Seville, 41010, Spain
West Clinical Research

Morehead City, North Carolina, 28557, United States

Conditions

Explore the condition pages connected to this study.

OSTEOARTHRITIS, KNEE